Orforglipron vs Tirzepatide

Orforglipron wins for: oral tablet convenience (no injections, no cold chain), flexible dosing and scheduling, and a PK profile forgiving of missed days. Best for protocol adherence, long-term maintenance, or those who want to sidestep injectable logistics. Side effect rates are slightly lower and more manageable at equivalent appetite suppression levels.

Tirzepatide wins for: unmatched fat-loss potency and glycemic effects. Dual GLP-1/GIP agonism drives much higher mean weight reduction (up to 21% at high-end dosing) and greater metabolic impact. For aggressive cut phases, contest prep, or cases where maximal appetite suppression is required, it's in a different class. Extensive community data, titration protocols, and established muscle-preservation strategies are widely vetted.

Pick Orforglipron if:

• An oral tablet protocol is the top priority (no injections, stable room-temp storage).
• The goal is appetite suppression or weight maintenance after a higher-potency injectable cycle.
• Flexibility (missed doses, shifting meal timing) is needed for travel or variable routine.
• GI side-effects from other GLP-1s were intolerable at target doses.
• Preserving lean mass is secondary to lifestyle compatibility and long-term adherence.

Pick Tirzepatide if:

• Maximal rapid fat reduction is the main goal (contest prep, aggressive cut).
• Previous runs of semaglutide/orforglipron hit a ceiling on appetite or glycemic effect.
• There's a titration plan for muscle and strength preservation (high protein, test base, training).
• Injectable prep (reconstituting peptide, storing cold) is not a barrier.
• The user wants access to extensive community protocols and known stacking strategies.